MDT-AP-1404
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 18.84
- os_event
- false
- age_years
- 3.82
- sex
- F
- new_clusters
- S2
- umap1_2d
- -0.688485581
- umap2_2d
- -7.698340295
- umap1_3d
- -3.522936196
- umap2_3d
- -2.800695711
- umap3_3d
- 6.081795416
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.520
- INTERFERON_GAMMA_RESPONSE+0.490
- ALLOGRAFT_REJECTION+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- INFLAMMATORY_RESPONSE+0.390
- NOTCH_SIGNALING+0.390
- TNFA_SIGNALING_VIA_NFKB+0.350
- ANGIOGENESIS+0.330
- HYPOXIA+0.310
- IL6_JAK_STAT3_SIGNALING+0.290
Top 10 suppressed
- PROTEIN_SECRETION-0.230
- DNA_REPAIR-0.210
- UNFOLDED_PROTEIN_RESPONSE-0.160
- SPERMATOGENESIS-0.150
- HEME_METABOLISM-0.100
- PEROXISOME-0.030
- BILE_ACID_METABOLISM-0.010
- FATTY_ACID_METABOLISM-0.010
- PI3K_AKT_MTOR_SIGNALING+0.020
- UV_RESPONSE_UP+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2086 | Med | Medulloblastoma | 0.921 |
| 2 | BS_J1AB8PMA | Med | Medulloblastoma | 0.906 |
| 3 | R303 | — | — | 0.881 |
| 4 | MDT-AP-0205 | Med | Medulloblastoma | 0.878 |
| 5 | MNG1029 | — | — | 0.873 |
| 6 | MDT-AP-0348 | Med | Medulloblastoma | 0.867 |
| 7 | AUR-AFUI-TTP1-A-1-0-R-A743-41 | — | C | 0.848 |
| 8 | MDT-AP-3275 | Med | Medulloblastoma | 0.847 |
| 9 | SRR10899973 | — | — | 0.841 |
| 10 | MDT-AP-1106 | Med | Medulloblastoma | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.390 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.230 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |